Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Philippe Moreau(Nantes Université), Antonio Palumbo(University of Turin), Douglas Joshua(Royal Prince Alfred Hospital), Luděk Pour(University Hospital Brno), Roman Hájek(University Hospital Ostrava), Thierry Façon(Hôpital Claude Huriez), Heinz Ludwig(Wilhelminen Hospital), Albert Oriol(Institut Català d'Oncologia), Hartmut Goldschmidt, Laura Rosiñol(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Jan Štraub(General University Hospital in Prague), Aleksandr Suvorov(The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic), Carla Araujo(Centre Hospitalier de la Côte Basque), Elena Rimashevskaya(Central Clinical Hospital No 2 named Semashko), Tomáš Pika(University Hospital Olomouc), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Katja Weisel(Universitätsklinikum Tübingen), Vesselina Goranova‐Marinova(University Multipurpose Hospital for Active Treatment "Sveti Georgi"), Anthony P. Schwarer(Box Hill Hospital), Leonard Minuk(London Health Sciences Centre), Tamás Masszi(Unified Szent István and Szent László Hospital), Ievgenii Karamanesht(Kyiv City Clinical Oncology Center), Massimo Offidani(Ospedali Riuniti Umberto I), Vânia Hungria(Irmandade da Santa Casa de Misericórdia de São Paulo), Andrew Spencer(Alfred Health), Robert Z. Orlowski(The University of Texas MD Anderson Cancer Center), Heidi H. Gillenwater(Amgen (United States)), Nehal Mohamed(Amgen (United States)), Shibao Feng(Amgen (United States)), Wee Joo Chng(National University Health System)
Cited by 844Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis